Yu-Waye Chu
Known title: Senior VP Clinical DevelopmentCIK: 0001854586
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| CTMX | ▼ Sell | Open Market | 21,279 | $137K | 3/17/2026 | View on chart |
| CTMX | ▲ Buy | Grant | 75,000 | $0 | 2/2/2026 | View on chart |
| CTMX | ▼ Sell | Open Market | 4,025 | $2K | 3/18/2025 | View on chart |
| CTMX | ▲ Buy | Grant | 57,500 | $0 | 2/4/2025 | View on chart |
| CTMX | ▲ Buy | Grant | 56,000 | $0 | 2/4/2025 | View on chart |
| CTMX | ▲ Buy | Grant | 26,250 | $0 | 1/18/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 2,317 | $15K | 4/18/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 215 | $1K | 4/18/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 7,825 | $41K | 1/10/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 4,062 | $144K | 4/19/2022 | View on chart |
| FATE | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 3,547 | $172K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 418 | $21K | 1/11/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 7,500 | $122K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 2,097 | $103K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 900 | $45K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 1,045 | $53K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 600 | $33K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 5 | $278 | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 1,822 | $95K | 12/10/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 1,031 | $55K | 12/10/2021 | View on chart |
| FATE | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences
CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.